Co-stimulation: considerations for CAR design

Carl June, M.D.
University of Pennsylvania


NIH Safety Symposium

June 15, 2010






T Cell Activation: antigenicity vs immunogenicity The concept of costimulation




Antigen:APC T cell interaction, no costimulation

Result: T cell anergy, apoptosis or suppression (Treg)



Antigen: APC T cell interaction with costimulation

Result: T cell activation, clonal expansion effector functions




Cytokines (IL-2, IL-12, IL-18)

"Immunological synapse"

Roles of CD28

- Induction and maintenance of cytokine and chemokine secretion
- Cell survival: bcl-X induction and promotes clonal expansion
- Enhanced telomerase activity
- Required for T cells to increase their glycolytic rate (PI3K and Akt)
- Down regulation of beta chemokine receptor expression




Environmental Signals (Ag, co-signaling, cytokines, chemokines)

Principles of costimulation co-signaling and co-inhibition


- Costimulatory signal transduction pathways downstream are conserved in mouse and man
- Expression of costimulatory molecules on lymphocyte subsets has substantial species specific variation (e.g. CD28 and ICOS)
- Lymphocyte subsets have distinct costimulatory requirements
 - CD28 is essential for CD4eff and Treg function
 - -4-1BB has a major role in CD8 Tcm function

Distinct Growth Requirements for Human CD4 and CD8 T Cells




Clin Immunol 2000; 96: 187


Efficient Induction of CD8 T Cell Proliferation by CD28:4-1BBL aAPC



T cell receptor-induced signal transduction pathways




TCR and CD28: Distinct Signal Transduction in Splenic CD4 and CD8 T Cells




- All mouse T cells express CD3 and CD28
- All mouse T cells flux calcium after CD3/TCR stimulation
- Only CD4 T cells flux calcium after CD28 stimulation

Distinct Effects of CD28 and ICOS on T Cell Effector Functions: Cytokine Secretion



Synchronous CD28 triggering can cause cytokine shock in mice and man

The NEW ENGLAND JOURNAL of MEDICINE



Saha 1996 JEM 183:2675

BRIEF REPORT

Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412


Ganesh Suntharalingam, F.R.C.A., Meghan R. Perry, M.R.C.P., Stephen Ward, F.R.C.A., Stephen J. Brett, M.D., Andrew Castello-Cortes, F.R.C.A., Michael D. Brunner, F.R.C.A., and Nicki Panoskaltsis, M.D., Ph.D.


SUMMARY

Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. Within 90 minutes after receiving a single intravenous dose of the drug, all six volunteers had a systemic inflammatory response characterized by a rapid induction of proinflammatory cytokines and accompanied by headache, myalgias, nausea, diarrhea, erythema, vasodilatation, and hypo-

NEJM 2006.355: 1018

CD28 is required for mouse exotoxin shock: dose dependence for serum TNF- α , IFN- γ and IL-2





Triggering endogenous CD28 can cause severe cytokine release in mice and humans

- Enterotoxin mediated shock in mice is CD28 dependent
- Humans develop cytokine release syndrome after infusion of agonistic CD28 mAbs
- Synchronous triggering predisposes
- Evidence for dose dependent effects

Co-signaling domains in CARs

TCRζ or FcεR1

- CARs with "first generation" TCR ζ or FceR1 epsilon trigger killing
- In primary T cells, $TCR\zeta$ signals in absence of costimulation lead to anergy

• CD28

- Studies to date indicate that the signaling domain needs to be membrane proximal.
- CD28 CARs have enhanced function and engraftment (preclinical and clinical data)
- CD28 Y170F and P187/190A CARs have attenuated function (Darcy).
- CD28 w mutated dileucine motif (LL => GG) have increased expression in mice (Geiger). Clinical studies pending.

Co-signaling domains in CARs

- 4-1BB (CD137)
 - 4-1BB signaling in CARs promotes survival of CARs in tumor bearing mice. Clinical studies underway.
- Other costimulatory and kinases tested in CARs
 - OX40 (Finney, Pule)
 - ICOS (Finney)
 - NKG2D (Sentman)
 - Lck (Geiger)

Preclinical Evaluation – Gene Therapy and Immunotherapy Agents

BUT... the approach by which safety data are obtained will differ:


GT, IT (gene-based) IT, Cell Products

- Biodistribution of vector/virus
- Kinetics of gene expression

- Immunogenicity to allogeneic cells
- Uncontrolled cell proliferation following ex vivo modifications


Ying Huang, Ph.D. FDA/CBER/OCTGT/DCEPT/PTB

Lentiviral Redirected T Cells Targeting Mesothelin or CD19




Carmine Carpenito Michael Milone

Redirected T Cells with Costimulatory Domains are Multitasking "Polyfunctional" T Cells



4-1BB Signaling: αCD19 CAR-induced T cell proliferation in vitro antigen-dependent and antigen-independent effects



Combinatorial Signaling Domains

| | Zeta only | 28:z | 41BB:z | 28:41BB:z |
|--------------------|--------------|------|--------|-----------|
| kill | ++ | ++ | ++ | ++ |
| cytokine | + | +++ | ++ | +++ |
| Prolifera- tion | + | +++ | +++ | +++ |
| In vivo survival | + | ++ | +++ | +++ |

Reverse Signaling and Potential Complex Interactions with CAR Extracellular Domains

- Reverse or 'back signaling' has been reported for costimulatory molecules, particularly type II membrane proteins of TNFR superfamily
- CD28 reported to induce stimulatory signals in dendritic cells via CD80 and CD86 (Orabona, Nature Immunology 5: 1134-42, 2004)
- The physiologic significance of reverse signaling remains unknown:
 - Con: Generally poor sequence conservation of ligands, in comparison to highly conserved sequences of CD28 family
 - Pro: A casein kinase I motif present in the cytoplasmic domain of members of the TNF ligand family is implicated in 'reverse signaling' (Watts, EMBO Journal 18: 2119)

CD28 family members: potential complexities with reverse signaling and promiscuity Tumor or Antigen Presenting Cell BTNL2 **B7-H4** PD-L1 PD-L2 **HVEM MHC** B7-2 B7-1 **B7-H3 ICOS-L** Co-inhibition Co-stin ulation CD28_{CTLA-4} PD-L1 CD160 BTLA PD-1 IgV-like domain (TREMR family) IgV-like domain IgC-like domain Immunoreceptor tyrosine-based switch motif Immunoreceptor tvrosine-based Inhibitory motif T-cell Tyr-X-X-Met Cvsteine-rich Domain (TNFR family)

Strategies to regulate the potency of costimulatory CARs

- 1. Inducible vs constitutive promoters
 - HIF1-α. (Makino et al. *J Immunol 171: 6534, 2003*)
- 2. Conditional "suicide" switches
- 3. Non-integrating expression systems
 - mRNA transduction (Zhao et al. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. *Molecular Therapy 13: 151, 2006*)
 - Protein transduction and protein painting. (Chen et al. 2000. Hierarchical Costimulator Thresholds for Distinct Immune Responses: Application of a Novel Two-Step Fc Fusion Protein Transfer Method 1. *J Immunol 164: 705, 2000*)

Costimulatory CARs: Summary

- The potency of CAR T cell is a function of the cell and the CAR.
- 2. Incorporation of a variety of costimulatory signaling domains enhances anti-tumor functions of CARs.
- 3. The available studies suggest that the function of the signaling domains in CARs replicates endogenous costimulatory functions.
- 4. Synchronized activation of CARs should be avoided to limit the potential for cytokine release syndrome.
- 5. A variety of evidence suggests that co-stimulation may have non-redundant functions in various lymphocyte subsets. Given that the expression of co-stimulatory molecules on lymphocyte subsets may vary between mouse and humans, some clinical effects are difficult to predict from pre-clinical studies.